humalog

The bearish case for Eli Lilly And Co (NYSE: LLY)'s stock is based on multiple concerns, but the stock's decline since the beginning of the year implies a better risk-to-reward profile, according to BMO Capital Markets.  The Analyst BMO's Alex Arfaei upgraded Eli Lilly from...

Analysts at Credit Suisse downgraded Eli Lilly and Co (NYSE: LLY) in October and just three months later, the firm believes another downgrade is warranted. The Analyst Credit Suisse's Vamil Divan downgraded Eli Lilly's stock from Neutral to Underperform with a price target lowered...

Despite a more than 200-percent gain in MannKind Corporation (NASDAQ: MNKD)'s stock over the past month alone analysts at H.C. Wainwright see even further upside ahead. The firm's Oren Livnat initiates coverage of MannKind's stock with a Buy rating and $7 price target, which represents a gain of...

Investors appear to be pleased with Eli Lilly and Co (NYSE: LLY)'s business after the company updated the investment community with short- and longer-term guidance. Eli Lilly's stock gained more than 5 percent on Thursday and was trading higher by another 1.50 percent at $72.45 ahead of Friday's...

A day after Eli Lilly and Co (NYSE: LLY) reported earnings and sales misses for the third quarter, Goldman Sachs reduced its revenue and EPS estimate by 1–3 percent for 2016–2025 based on the conservative expectations of Jardiance, Humalog and Portrazza. However, the firm thinks that...

The meat of large-cap pharmaceutical earnings season starts this week. Johnson & Johnson (NYSE: JNJ)’s strong Q1 report last week has Credit Suisse analyst Vamil Divan hopeful that AbbVie Inc (NYSE: ABBV), Bristol-Myers Squibb Co (NYSE: BMY) and Eli Lilly and Co (NYSE: LLY) will be able...